Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026314 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL28929577 | 0.91 | SMN1; SMN2 (0.53) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL7877130 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL22394902 | 0.86 | — | — | |
| SCHEMBL23419143 | 0.83 | NAAA (0.58) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL61158 | 0.83 | NAAA (0.58) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL19757607 | 0.81 | EPHX1 (0.65) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL3184451 | 0.81 | NAAA (0.66) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL4678443 | 0.80 | NAAA (0.55) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 | |
| SCHEMBL13300769 | 0.79 | NAAA (0.64) | EPHX1SMN1; SMN2HSD17B10HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| EP-0641781-B1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-26 | — | — | EP | claimed |
| JP-4187666-A | — | — | None | — | — | JP | disclosed |
| JP-2124096-A | — | — | None | — | — | JP | disclosed |
| US-9120776-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| WO-2011157748-A1 | 5-ARYL ISOXAZOLINES FOR CONTROLLING PESTS | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-0956031-B1 | INHIBITION OF 26 S AND 20 S PROTEASOME BY INDANONES | CV THERAPEUTICS INC (US) | 2005-06-15 | — | — | EP | disclosed |
| JP-2002322138-A | METHOD FOR PRODUCING AMINOMETHYLCYCLOHEXANECARBOOXYLIC ACID | MITSUBISHI GAS CHEM CO INC | 2002-11-08 | — | — | JP | disclosed |
| EP-1087940-A1 | NOVEL COMPOUNDS USEFUL IN PAIN MANAGEMENT | AstraZeneca AB (SE) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067203-A1 | NOVEL COMPOUNDS USEFUL IN PAIN MANAGEMENT | ASTRAZENECA AB (SE) | 1999-12-29 | — | — | WO | disclosed |
| EP-0669317-A1 | Prolineamide derivatives | Mitsubishi Chemical Corporation (JP) | 1995-08-30 | — | — | EP | disclosed |
| JP-H04187666-A | CYCLOHEXANECARBOXAMIDE DERIVATIVE, ENZYMIC INHIBITOR AND ANTIULCER AGENT | ASAHI CHEM IND CO LTD | 1992-07-06 | — | — | JP | disclosed |
| JP-H02124096-A | PREPARATION OF TRANS-4-CYANOCYCLOHEXANECARBOXYLIC ACID AMIDE | ASAHI CHEM IND CO LTD | 1990-05-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | RORC, RORB, RORA | EPHX1 2492/4885SMN1; SMN2 3372/4885HSD17B10 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.